-- Launch of InnerCool's new CoolBlue(TM) surface temperature modulation
system, which is designed to provide effective patient temperature
control in less acute patients or in clinical settings best suited to
prolonged temperature management.
-- Completion of development of InnerCool's next-generation RapidBlue(TM)
endovascular cooling system, including an enhanced console and
disposable catheter, which is designed to cool patients rapidly and
controllably, and provide effective rewarming as well as cooling.
-- Publication in the Journal of American College of Cardiology of
positive findings from a pooled by-patient analysis of the AGENT-3 and
AGENT-4 Phase 2b/3 clinical trials for Generx. Among the findings
reported, a pre-specified analysis showed significant improvements in
multiple clinical measures of heart disease among women who received
Generx(TM) as compared to women in the placebo control group.
-- Completion of a $21.5 million equity financing with institutional and
other accredited investors and listing on the American Stock Exchange
(AMEX) under the new trading symbol CXM.
-- Licensing agreement with the University of Texas Health Science Center
at Houston for the clinical research, development and
commercialization of Caffeinol as a potential therapeutic for use in
acute ischemic stroke patients. A Phase 2a study has been proposed to
the National Institute of Neurological Disorders and Stroke, part of
the National Institutes of Health (NIH), to assess the safety and
efficacy of induced hypothermia and Caffeinol, both individually and
in combination, in an estimated 400 patients presenting within three
hours of an acute stroke.
-- Initiation of pre-clinical studies supported by
|SOURCE Cardium Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved